BioPharma Dive June 8, 2023
Jonathan Gardner

Moderna presented new data at ASCO for its melanoma shot, highlighting progress with a personalized approach that’s also being pursued by BioNTech and Gritstone.

The development of therapeutic vaccines for cancer has met repeated disappointment over the years, as treatments aimed at cancers of the brain, lung and kidney have failed in clinical testing.

But now, developers like Moderna, BioNTech and Gritstone Bio are pushing forward with personalized, messenger RNA vaccines that have revitalized hopes these treatments could boost human immunity to keep cancer at bay.

The American Society for Clinical Oncology’s annual meeting, held this week in Chicago, was the latest forum for Moderna and partner Merck & Co. to disclose data for a cancer shot they’re developing, called...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Cancer Therapy and The Intestinal Microbiome
Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions
GLP-1 Prescribing Shifts From Type 2 Diabetes to Obesity
A New Target To Boost Cancer Immunotherapy: LAG-3
STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies

Share This Article